drugset / Trial / NCT00229177

Study of ONO-2506 in Patients With Acute Ischemic Stroke

NCT00229177 ↗

Phase 2/3 Completed 757 enrolled Ono Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of ONO-2506 compared to placebo in patients with acute ischemic stroke.

Timeline

Start
2005-09
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ARUNDIC ACID Small molecule 8 mg/kg Intravenous
Subject ARUNDIC ACID Small molecule 12 mg/kg Intravenous

Indications